Abstract:Abstract Background Pancreatic cancer (PC) is a highly fatal and aggressive disease with its incidence and mortality quite discouraging. An effective prediction model is urgently needed for the accurate assessment of patients’ prognosis to assist clinical decision-making. Methods Gene expression data and clinicopathological data of the samples were acquired from The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), and Gene Expression Omnibus (GEO) databases. Differential expressed genes (DEGs) analysis, univariate Cox regression analysis, least absolute shrinkage and selection operator (LASSO) regression analysis, random forest screening and multivariate Cox regression analysis were applied to construct the risk signature. The effectiveness and independence of the model were validated by time-dependent receiver operating characteristic (ROC) curve, Kaplan–Meier (KM) survival analysis and survival point graph in training set, test set, TCGA entire set and GSE57495 set. The validity of the core gene was verified by immunohistochemistry and our own independent cohort. Meanwhile, functional enrichment analysis of DEGs between the high and low risk groups revealed the potential biological pathways. Finally, CMap database and drug sensitivity assay were utilized to identify potential small molecular drugs as the risk model-related treatments for PC patients. Results Four histone modification-related genes were identified to establish the risk signature, including CBX8, CENPT, DPY30 and PADI1. The predictive performance of risk signature was validated in training set, test set, TCGA entire set and GSE57495 set, with the areas under ROC curve (AUCs) for 3-year survival were 0.773, 0.729, 0.775 and 0.770 respectively. Furthermore, KM survival analysis, univariate and multivariate Cox regression analysis proved it as an independent prognostic factor. Mechanically, functional enrichment analysis showed that the poor prognosis of high-risk population was related to the metabolic disorders caused by inadequate insulin secretion, which was fueled by neuroendocrine aberration. Lastly, a cluster of small molecule drugs were identified with significant potentiality in treating PC patients. Conclusions Based on a histone modification-related gene signature, our model can serve as a reliable prognosis assessment tool and help to optimize the treatment for PC patients. Meanwhile, a cluster of small molecule drugs were also identified with significant potentiality in treating PC patients.

Importance of gene expression signatures in pancreatic cancer prognosis and the establishment of a prediction model

Importance of gene expression signatures in pancreatic cancer prognosis and the establishment of a prediction model

Identification of Spindle and Kinetochore-Associated Family Genes As Therapeutic Targets and Prognostic Biomarkers in Pancreas Ductal Adenocarcinoma Microenvironment

Bioinformatics-Based Identification of Tumor Microenvironment-Related Prognostic Genes in Pancreatic Cancer

Construction of a prognostic model with histone modification-related genes and identification of potential drugs in pancreatic cancer

Gene Signature Associated with Neuro‐endocrine Activity Predicting Prognosis of Pancreatic Carcinoma

Liquid-liquid phase separation-related features of PYGB/ACTR3/CCNA2/ITGB1/ATP8A1/RAP1GAP2 predict the prognosis of pancreatic cancer

Prognostic biomarkers of pancreatic cancer identified based on a competing endogenous RNA regulatory network

Predicting Postoperative Prognosis of Pancreatic Cancer Using a CT-Based Radio-Clinical Model: Exploring Biological Functions

Identification and prognostic analysis of biomarkers to predict the progression of pancreatic cancer patients

Identification of a Novel Risk Model: A Five-Gene Prognostic Signature for Pancreatic Cancer

Identification by genetic algorithm optimized back propagation artificial neural network and validation of a four-gene signature for diagnosis and prognosis of pancreatic cancer

Screening and discrimination of optimal prognostic genes for pancreatic cancer based on a prognostic prediction model

Single-cell sequencing and establishment of an 8-gene prognostic model for pancreatic cancer patients

Five Gene Signatures Were Identified in the Prediction of Overall Survival in Resectable Pancreatic Cancer

Prognostic Utility of TME-associated Genes in Pancreatic Cancer.

Development and validation of prognostic and diagnostic model for pancreatic ductal adenocarcinoma based on scRNA-seq and bulk-seq datasets

Development and Clinical Validation of a Novel 9-Gene Prognostic Model Based on Multi-Omics in Pancreatic Adenocarcinoma.

Establishment of a prognostic prediction system based on tumor microenvironment of pancreatic cancer

Identification of Prognosis-Related Molecular Subgroups and Construction of a Prognostic Prediction Model Using Immune-Related Genes in Pancreatic Cancer

A protein-based prognostic model for pancreatic ductal adenocarcinoma: Construction and validation